Surrey Heartlands

Joint Formulary & PAD

Metolazone - Hypertension

You are here : Home > Formulary Search > Metolazone - Hypertension

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
NFD1
Restrictions / Comments :
Important
The licensed (Xaqua) and unlicensed (Zaroxolyn) tablets have different bioavailabilities. These products are not interchangable=Prescribe by Brand

Documentation

Webpage
Differences-between-metolazone-preparations-and-safety-considerations

PAD Profile

ChemicalSubstance :
Metolazone
Indication :
Hypertension
Group Name :
Keywords :
Brand Names Include :
Xaqua
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Hypertension
Supporting Documents :
1

Other Indications

Below are listed other indications that Metolazone is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Hypertension.

Committee Recommendations (1)

09 Nov 22 - Surrey Heartlands Medicines Safety Committee (MSC)

Although there may have been historic prescribing of metolazone for hypertension in parts of Surrey, metolazone has not been formally assessed for this indication in Surrey Heartlands.  Prescribing for hypertension should be in line with NICE NG136 whilst the local Surrey Heartlands hypertension guidelines are being updated (https://surreyccg.res-systems.net/PAD/Guidelines/Detail/4397)

Where metolozone is being prescribed, please take note of the important safety information below:

When initiating patients on metolazone the licensed, branded Xaqua preparation should be prescribed.

Any switch between products should take into account the difference in bioavailability between Xaqua and other available unlicensed products.

Switching from the unlicensed (imported) product to Xaqua may require a reduction in dose by half, or for the same dose to be used but adjust the frequency from daily to alternate days.

The tablets have a single score-line and can be divided into equal halves.

Update March 2023:

  • Refer any patients who are taking unlicensed metolazone and have not been reviewed to the prescribing specialist for review and consideration for switching to the licensed product Xaqua